ИЗУЧЕНИЕ ВЗАИМОДЕЙСТВИЯ ПРОТЕИНКИНАЗЫ И ПРОИЗВОДНЫХ ХИНАЗОЛИНА С ИСПОЛЬЗОВАНИЕМ МОЛЕКУЛЯРНОГО ДОКИНГА
В данном исследовании взаимодействие производных хиназолина с протеин киназой (код PDB: 4AQC) изучалось с помощью молекулярного докинга. Результаты показали, что эти производные связываются с высокой степенью сродства к активным центрам выбранного белка, что помогает объяснить их биологическую активность. Результаты стыковки могут быть полезны при разработке новых лекарственных препаратов.
1. Khan I., Zaib S., Batool S., Abbas N., Ashraf Z., Iqbal J., Saeed A., Quinazolines and quinazolinones as ubiquitous structural fragments in medicinal chemistry: an update on the development of synthetic methods and pharmacological diversification, Bioorg. Med. Chem. 24 (2016) 2361-2381.
2. Ismail R.S.M., Ismail N.S.M., Abuserii S., Abou El Ella D.A., Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents, Future J. Pharm. Sci. 2 (2016) 9-19.
3. Alagarsamy V., Chitra K., Saravanan G., Solomon V.R., Sulthana M.T., Narendhar B., An overview of quinazolines: pharmacological significance and recent developments, Eur. J. Med. Chem. 151 (2018) 628-685.
4. Singh K., Sharma P.P., Kumar A., Chaudhary A., Roy R.K., 4-Aminoquinazoline analogs: a novel class of anticancer agents, Mini Rev. Med. Chem. 13 (2013) 1177-1194.
5. Lipunova G.N., Nosova E.V., Charushin V.N., Chupakhin O.N., Synthesis and antitumour activity of 4-aminoquinazoline derivatives, Russ. Chem. Rev. 85 (2016) 759-793.
6. Wang, D., Gao, F, Quinazoline derivatives: synthesis and bioactivities. Chem. Cent. J. 7, 95, (2013).
7. Asif, M., Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivative. Int. J. Med. Chem. (2014) 395637.
8. Qiao, H., Zhao, D., Shi, H., et al. Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3. Oncol. Rep. 34, (2015) 1875–1882.
9. Yang, S.H., Khadka, D.B., Cho, S.H., et al., Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors. Bioorg. Med. Chem. 19, (2011) 968–977.
10. Jyothi Buggana, S.; Paturi, M.C.; Perka, H.; Gade, D.R.; Vvs, R.P. Novel 2,4-disubstituted quinazolines as cytotoxic agents and JAK2 inhibitors: Synthesis, in vitro evaluation and molecular dynamics studies. Comput. Biol. Chem. 79 (2019) 110– 118.
11. Das, D.; Hong, J. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. Eur. J. Med. Chem. 170 (2019) 55–72. 12. Aly, A.A., Synthesis and antimicrobial activity of some annelated quinazoline derivatives. J. Chin. Chem. Soc. 54 (437) (2007) 46.
13. Hans-Dieter Höltje, Rainer Willett, Pierre J. van der Greef Molecular Docking: Methods and Applications, Wiley-VCH, 2004, - 290 pages.
14. Kuntz, I.D., et al., Molecular docking: a powerful approach for structure-based drug design, Nature, 1982.
15. Kitchen, D.B., et al., Protein-ligand docking and virtual screening with docking, Nature Reviews Drug Discovery, 2004.
16. Trott, O., & Olson, A.J., Recent advances in molecular docking: a review, Journal of Computational Chemistry, 2010.
17. Jacobson, M.P., et al., Docking of proteins and ligands: Applications to drug design, Current Opinion in Structural Biology, 2004.
18. Gilson, M.K., & Zhou, H.-X., Challenges and advances in the use of molecular docking to predict protein-ligand binding, Annual Review of Biophysics, 2007.
19. Gasteiger, J., & Engel, T., Molecular docking and virtual screening: A review, Bioinformatics, 2003.
Copyright (c) 2025 Вестник НУУз
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-ShareAlike» («Атрибуция — Некоммерческое использование — На тех же условиях») 4.0 Всемирная.
.jpg)
2.png)
